 | • レポートコード：MR2211MG12767 • 出版社/出版日：Market Monitor Global / 2022年11月 • レポート形態：英文、PDF、73ページ • 納品方法：Eメール（納期：2-3日） • 産業分類：製薬・ヘルスケア |
| Single User | ￥481,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥625,300 (USD4,225) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査資料は次の情報を含め、組換えヒトエリスロポエチン注射のグローバル市場規模と予測を記載しています。・組換えヒトエリスロポエチン注射のグローバル市場：売上、2017年-2022年、2023年-2028年 ・組換えヒトエリスロポエチン注射のグローバル市場：販売量、2017年-2022年、2023年-2028年 ・世界のトップ5企業、2021年 組換えヒトエリスロポエチン注射のグローバル市場規模は2021年に000Mドルと評価され、予測期間中に000％のCAGRで2028年までに000Mドルに達すると予測されています。米国市場は2021年に000Mドルと推定されており、中国は2028年までに000Mドルに達すると予測されています。「0.3ml枝」セグメントは今後6年間、000%のCAGRで2028年までに000Mドルに成長すると予測されています。 組換えヒトエリスロポエチン注射のグローバル主要企業は、Roche、LG Chem、Kexing Biopharm、3SBio Group、Harbin Pharmaceutical Group Holding、Dong-E-E-Jiao、Humanwell Healthcare、Ncpc Genetech Biotechnology、Shandong E-hua Biotech Pharmaceutical、Intas Pharmaceuticals、PeproTech、WELLONA PHARMA、SI HUAN SHENG WU、Shanxi Weiqidaguangming Pharmaceuticalなどです。2021年にトップ5企業がグローバル売上シェアの約000%を占めています。 マーケットモニターグローバル（MMG）社は、組換えヒトエリスロポエチン注射のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の組換えヒトエリスロポエチン注射市場：タイプ別、2017年-2022年、2023年-2028年 世界の組換えヒトエリスロポエチン注射市場：タイプ別市場シェア、2021年 ・0.3ml枝、0.6ml枝、1ml枝、その他 世界の組換えヒトエリスロポエチン注射市場：用途別、2017年-2022年、2023年-2028年 世界の組換えヒトエリスロポエチン注射市場：用途別市場シェア、2021年 ・腎不全性貧血、非腎性貧血 世界の組換えヒトエリスロポエチン注射市場：地域・国別、2017年-2022年、2023年-2028年 世界の組換えヒトエリスロポエチン注射市場：地域別市場シェア、2021年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における組換えヒトエリスロポエチン注射のグローバル売上、2017年-2022年 ・主要企業における組換えヒトエリスロポエチン注射のグローバル売上シェア、2021年 ・主要企業における組換えヒトエリスロポエチン注射のグローバル販売量、2017年-2022年 ・主要企業における組換えヒトエリスロポエチン注射のグローバル販売量シェア、2021年 さらに、当レポートは主要企業のプロファイルを提示します。 Roche、LG Chem、Kexing Biopharm、3SBio Group、Harbin Pharmaceutical Group Holding、Dong-E-E-Jiao、Humanwell Healthcare、Ncpc Genetech Biotechnology、Shandong E-hua Biotech Pharmaceutical、Intas Pharmaceuticals、PeproTech、WELLONA PHARMA、SI HUAN SHENG WU、Shanxi Weiqidaguangming Pharmaceutical ************************************************************* ・調査・分析レポートの概要 組換えヒトエリスロポエチン注射市場の定義 市場セグメント 世界の組換えヒトエリスロポエチン注射市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の組換えヒトエリスロポエチン注射市場規模 世界の組換えヒトエリスロポエチン注射市場規模：2021年 VS 2028年 世界の組換えヒトエリスロポエチン注射市場規模と予測 2017年-2028年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの組換えヒトエリスロポエチン注射の売上 グローバルトップ3およびトップ5企業、2021年売上ベース グローバル企業の組換えヒトエリスロポエチン注射製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：0.3ml枝、0.6ml枝、1ml枝、その他 組換えヒトエリスロポエチン注射のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：腎不全性貧血、非腎性貧血 組換えヒトエリスロポエチン注射の用途別グローバル売上・予測 ・地域別市場分析 地域別組換えヒトエリスロポエチン注射市場規模 2021年と2028年 地域別組換えヒトエリスロポエチン注射売上・予測 北米市場 - アメリカの組換えヒトエリスロポエチン注射市場規模2017年-2028年 - カナダの組換えヒトエリスロポエチン注射市場規模2017年-2028年 - メキシコの組換えヒトエリスロポエチン注射市場規模2017年-2028年 ヨーロッパ市場 - ドイツの組換えヒトエリスロポエチン注射市場規模2017年-2028年 - フランスの組換えヒトエリスロポエチン注射市場規模2017年-2028年 - イギリスの組換えヒトエリスロポエチン注射市場規模2017年-2028年 - イタリアの組換えヒトエリスロポエチン注射市場規模2017年-2028年 - ロシアの組換えヒトエリスロポエチン注射市場規模2017年-2028年 アジア市場 - 中国の組換えヒトエリスロポエチン注射市場規模2017年-2028年 - 日本の組換えヒトエリスロポエチン注射市場規模2017年-2028年 - 韓国の組換えヒトエリスロポエチン注射市場規模2017年-2028年 - 東南アジアの組換えヒトエリスロポエチン注射市場規模2017年-2028年 - インドの組換えヒトエリスロポエチン注射市場規模2017年-2028年 南米市場 - ブラジルの組換えヒトエリスロポエチン注射市場規模2017年-2028年 - アルゼンチンの組換えヒトエリスロポエチン注射市場規模2017年-2028年 中東・アフリカ市場 - トルコの組換えヒトエリスロポエチン注射市場規模2017年-2028年 - イスラエルの組換えヒトエリスロポエチン注射市場規模2017年-2028年 - サウジアラビアの組換えヒトエリスロポエチン注射市場規模2017年-2028年 - UAEの組換えヒトエリスロポエチン注射市場規模2017年-2028年 ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Roche、LG Chem、Kexing Biopharm、3SBio Group、Harbin Pharmaceutical Group Holding、Dong-E-E-Jiao、Humanwell Healthcare、Ncpc Genetech Biotechnology、Shandong E-hua Biotech Pharmaceutical、Intas Pharmaceuticals、PeproTech、WELLONA PHARMA、SI HUAN SHENG WU、Shanxi Weiqidaguangming Pharmaceutical ... |
Recombinant human erythropoietin injection (CHO cells) is clinically used for anemia caused by renal insufficiency, including hemodialysis, peritoneal dialysis and non dialysis patients with chronic renal failure.
This report contains market size and forecasts of Recombinant Human Erythropoietin Injection in global, including the following market information:
Global Recombinant Human Erythropoietin Injection Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Recombinant Human Erythropoietin Injection Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Recombinant Human Erythropoietin Injection companies in 2021 (%)
The global Recombinant Human Erythropoietin Injection market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
0.3ml Branch Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Recombinant Human Erythropoietin Injection include Roche, LG Chem, Kexing Biopharm, 3SBio Group, Harbin Pharmaceutical Group Holding, Dong-E-E-Jiao, Humanwell Healthcare, Ncpc Genetech Biotechnology and Shandong E-hua Biotech Pharmaceutical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Recombinant Human Erythropoietin Injection manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Recombinant Human Erythropoietin Injection Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Human Erythropoietin Injection Market Segment Percentages, by Type, 2021 (%)
0.3ml Branch
0.6ml Branch
1ml Branch
Others
Global Recombinant Human Erythropoietin Injection Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Human Erythropoietin Injection Market Segment Percentages, by Application, 2021 (%)
Renal Failure Anemia
Non Renal Anemia
Global Recombinant Human Erythropoietin Injection Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Recombinant Human Erythropoietin Injection Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Recombinant Human Erythropoietin Injection revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Recombinant Human Erythropoietin Injection revenues share in global market, 2021 (%)
Key companies Recombinant Human Erythropoietin Injection sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Recombinant Human Erythropoietin Injection sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
LG Chem
Kexing Biopharm
3SBio Group
Harbin Pharmaceutical Group Holding
Dong-E-E-Jiao
Humanwell Healthcare
Ncpc Genetech Biotechnology
Shandong E-hua Biotech Pharmaceutical
Intas Pharmaceuticals
PeproTech
WELLONA PHARMA
SI HUAN SHENG WU
Shanxi Weiqidaguangming Pharmaceutical
1 Introduction to Research & Analysis Reports
1.1 Recombinant Human Erythropoietin Injection Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Recombinant Human Erythropoietin Injection Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Recombinant Human Erythropoietin Injection Overall Market Size
2.1 Global Recombinant Human Erythropoietin Injection Market Size: 2021 VS 2028
2.2 Global Recombinant Human Erythropoietin Injection Revenue, Prospects & Forecasts: 2017-2028
2.3 Global Recombinant Human Erythropoietin Injection Sales: 2017-2028
3 Company Landscape
3.1 Top Recombinant Human Erythropoietin Injection Players in Global Market
3.2 Top Global Recombinant Human Erythropoietin Injection Companies Ranked by Revenue
3.3 Global Recombinant Human Erythropoietin Injection Revenue by Companies
3.4 Global Recombinant Human Erythropoietin Injection Sales by Companies
3.5 Global Recombinant Human Erythropoietin Injection Price by Manufacturer (2017-2022)
3.6 Top 3 and Top 5 Recombinant Human Erythropoietin Injection Companies in Global Market, by Revenue in 2021
3.7 Global Manufacturers Recombinant Human Erythropoietin Injection Product Type
3.8 Tier 1, Tier 2 and Tier 3 Recombinant Human Erythropoietin Injection Players in Global Market
3.8.1 List of Global Tier 1 Recombinant Human Erythropoietin Injection Companies
3.8.2 List of Global Tier 2 and Tier 3 Recombinant Human Erythropoietin Injection Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Recombinant Human Erythropoietin Injection Market Size Markets, 2021 & 2028
4.1.2 0.3ml Branch
4.1.3 0.6ml Branch
4.1.4 1ml Branch
4.1.5 Others
4.2 By Type – Global Recombinant Human Erythropoietin Injection Revenue & Forecasts
4.2.1 By Type – Global Recombinant Human Erythropoietin Injection Revenue, 2017-2022
4.2.2 By Type – Global Recombinant Human Erythropoietin Injection Revenue, 2023-2028
4.2.3 By Type – Global Recombinant Human Erythropoietin Injection Revenue Market Share, 2017-2028
4.3 By Type – Global Recombinant Human Erythropoietin Injection Sales & Forecasts
4.3.1 By Type – Global Recombinant Human Erythropoietin Injection Sales, 2017-2022
4.3.2 By Type – Global Recombinant Human Erythropoietin Injection Sales, 2023-2028
4.3.3 By Type – Global Recombinant Human Erythropoietin Injection Sales Market Share, 2017-2028
4.4 By Type – Global Recombinant Human Erythropoietin Injection Price (Manufacturers Selling Prices), 2017-2028
5 Sights By Application
5.1 Overview
5.1.1 By Application – Global Recombinant Human Erythropoietin Injection Market Size, 2021 & 2028
5.1.2 Renal Failure Anemia
5.1.3 Non Renal Anemia
5.2 By Application – Global Recombinant Human Erythropoietin Injection Revenue & Forecasts
5.2.1 By Application – Global Recombinant Human Erythropoietin Injection Revenue, 2017-2022
5.2.2 By Application – Global Recombinant Human Erythropoietin Injection Revenue, 2023-2028
5.2.3 By Application – Global Recombinant Human Erythropoietin Injection Revenue Market Share, 2017-2028
5.3 By Application – Global Recombinant Human Erythropoietin Injection Sales & Forecasts
5.3.1 By Application – Global Recombinant Human Erythropoietin Injection Sales, 2017-2022
5.3.2 By Application – Global Recombinant Human Erythropoietin Injection Sales, 2023-2028
5.3.3 By Application – Global Recombinant Human Erythropoietin Injection Sales Market Share, 2017-2028
5.4 By Application – Global Recombinant Human Erythropoietin Injection Price (Manufacturers Selling Prices), 2017-2028
6 Sights by Region
6.1 By Region – Global Recombinant Human Erythropoietin Injection Market Size, 2021 & 2028
6.2 By Region – Global Recombinant Human Erythropoietin Injection Revenue & Forecasts
6.2.1 By Region – Global Recombinant Human Erythropoietin Injection Revenue, 2017-2022
6.2.2 By Region – Global Recombinant Human Erythropoietin Injection Revenue, 2023-2028
6.2.3 By Region – Global Recombinant Human Erythropoietin Injection Revenue Market Share, 2017-2028
6.3 By Region – Global Recombinant Human Erythropoietin Injection Sales & Forecasts
6.3.1 By Region – Global Recombinant Human Erythropoietin Injection Sales, 2017-2022
6.3.2 By Region – Global Recombinant Human Erythropoietin Injection Sales, 2023-2028
6.3.3 By Region – Global Recombinant Human Erythropoietin Injection Sales Market Share, 2017-2028
6.4 North America
6.4.1 By Country – North America Recombinant Human Erythropoietin Injection Revenue, 2017-2028
6.4.2 By Country – North America Recombinant Human Erythropoietin Injection Sales, 2017-2028
6.4.3 US Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.4.4 Canada Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.4.5 Mexico Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.5 Europe
6.5.1 By Country – Europe Recombinant Human Erythropoietin Injection Revenue, 2017-2028
6.5.2 By Country – Europe Recombinant Human Erythropoietin Injection Sales, 2017-2028
6.5.3 Germany Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.5.4 France Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.5.5 U.K. Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.5.6 Italy Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.5.7 Russia Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.5.8 Nordic Countries Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.5.9 Benelux Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.6 Asia
6.6.1 By Region – Asia Recombinant Human Erythropoietin Injection Revenue, 2017-2028
6.6.2 By Region – Asia Recombinant Human Erythropoietin Injection Sales, 2017-2028
6.6.3 China Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.6.4 Japan Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.6.5 South Korea Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.6.6 Southeast Asia Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.6.7 India Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.7 South America
6.7.1 By Country – South America Recombinant Human Erythropoietin Injection Revenue, 2017-2028
6.7.2 By Country – South America Recombinant Human Erythropoietin Injection Sales, 2017-2028
6.7.3 Brazil Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.7.4 Argentina Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Recombinant Human Erythropoietin Injection Revenue, 2017-2028
6.8.2 By Country – Middle East & Africa Recombinant Human Erythropoietin Injection Sales, 2017-2028
6.8.3 Turkey Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.8.4 Israel Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.8.5 Saudi Arabia Recombinant Human Erythropoietin Injection Market Size, 2017-2028
6.8.6 UAE Recombinant Human Erythropoietin Injection Market Size, 2017-2028
7 Manufacturers & Brands Profiles
7.1 Roche
7.1.1 Roche Corporate Summary
7.1.2 Roche Business Overview
7.1.3 Roche Recombinant Human Erythropoietin Injection Major Product Offerings
7.1.4 Roche Recombinant Human Erythropoietin Injection Sales and Revenue in Global (2017-2022)
7.1.5 Roche Key News
7.2 LG Chem
7.2.1 LG Chem Corporate Summary
7.2.2 LG Chem Business Overview
7.2.3 LG Chem Recombinant Human Erythropoietin Injection Major Product Offerings
7.2.4 LG Chem Recombinant Human Erythropoietin Injection Sales and Revenue in Global (2017-2022)
7.2.5 LG Chem Key News
7.3 Kexing Biopharm
7.3.1 Kexing Biopharm Corporate Summary
7.3.2 Kexing Biopharm Business Overview
7.3.3 Kexing Biopharm Recombinant Human Erythropoietin Injection Major Product Offerings
7.3.4 Kexing Biopharm Recombinant Human Erythropoietin Injection Sales and Revenue in Global (2017-2022)
7.3.5 Kexing Biopharm Key News
7.4 3SBio Group
7.4.1 3SBio Group Corporate Summary
7.4.2 3SBio Group Business Overview
7.4.3 3SBio Group Recombinant Human Erythropoietin Injection Major Product Offerings
7.4.4 3SBio Group Recombinant Human Erythropoietin Injection Sales and Revenue in Global (2017-2022)
7.4.5 3SBio Group Key News
7.5 Harbin Pharmaceutical Group Holding
7.5.1 Harbin Pharmaceutical Group Holding Corporate Summary
7.5.2 Harbin Pharmaceutical Group Holding Business Overview
7.5.3 Harbin Pharmaceutical Group Holding Recombinant Human Erythropoietin Injection Major Product Offerings
7.5.4 Harbin Pharmaceutical Group Holding Recombinant Human Erythropoietin Injection Sales and Revenue in Global (2017-2022)
7.5.5 Harbin Pharmaceutical Group Holding Key News
7.6 Dong-E-E-Jiao
7.6.1 Dong-E-E-Jiao Corporate Summary
7.6.2 Dong-E-E-Jiao Business Overview
7.6.3 Dong-E-E-Jiao Recombinant Human Erythropoietin Injection Major Product Offerings
7.6.4 Dong-E-E-Jiao Recombinant Human Erythropoietin Injection Sales and Revenue in Global (2017-2022)
7.6.5 Dong-E-E-Jiao Key News
7.7 Humanwell Healthcare
7.7.1 Humanwell Healthcare Corporate Summary
7.7.2 Humanwell Healthcare Business Overview
7.7.3 Humanwell Healthcare Recombinant Human Erythropoietin Injection Major Product Offerings
7.7.4 Humanwell Healthcare Recombinant Human Erythropoietin Injection Sales and Revenue in Global (2017-2022)
7.7.5 Humanwell Healthcare Key News
7.8 Ncpc Genetech Biotechnology
7.8.1 Ncpc Genetech Biotechnology Corporate Summary
7.8.2 Ncpc Genetech Biotechnology Business Overview
7.8.3 Ncpc Genetech Biotechnology Recombinant Human Erythropoietin Injection Major Product Offerings
7.8.4 Ncpc Genetech Biotechnology Recombinant Human Erythropoietin Injection Sales and Revenue in Global (2017-2022)
7.8.5 Ncpc Genetech Biotechnology Key News
7.9 Shandong E-hua Biotech Pharmaceutical
7.9.1 Shandong E-hua Biotech Pharmaceutical Corporate Summary
7.9.2 Shandong E-hua Biotech Pharmaceutical Business Overview
7.9.3 Shandong E-hua Biotech Pharmaceutical Recombinant Human Erythropoietin Injection Major Product Offerings
7.9.4 Shandong E-hua Biotech Pharmaceutical Recombinant Human Erythropoietin Injection Sales and Revenue in Global (2017-2022)
7.9.5 Shandong E-hua Biotech Pharmaceutical Key News
7.10 Intas Pharmaceuticals
7.10.1 Intas Pharmaceuticals Corporate Summary
7.10.2 Intas Pharmaceuticals Business Overview
7.10.3 Intas Pharmaceuticals Recombinant Human Erythropoietin Injection Major Product Offerings
7.10.4 Intas Pharmaceuticals Recombinant Human Erythropoietin Injection Sales and Revenue in Global (2017-2022)
7.10.5 Intas Pharmaceuticals Key News
7.11 PeproTech
7.11.1 PeproTech Corporate Summary
7.11.2 PeproTech Recombinant Human Erythropoietin Injection Business Overview
7.11.3 PeproTech Recombinant Human Erythropoietin Injection Major Product Offerings
7.11.4 PeproTech Recombinant Human Erythropoietin Injection Sales and Revenue in Global (2017-2022)
7.11.5 PeproTech Key News
7.12 WELLONA PHARMA
7.12.1 WELLONA PHARMA Corporate Summary
7.12.2 WELLONA PHARMA Recombinant Human Erythropoietin Injection Business Overview
7.12.3 WELLONA PHARMA Recombinant Human Erythropoietin Injection Major Product Offerings
7.12.4 WELLONA PHARMA Recombinant Human Erythropoietin Injection Sales and Revenue in Global (2017-2022)
7.12.5 WELLONA PHARMA Key News
7.13 SI HUAN SHENG WU
7.13.1 SI HUAN SHENG WU Corporate Summary
7.13.2 SI HUAN SHENG WU Recombinant Human Erythropoietin Injection Business Overview
7.13.3 SI HUAN SHENG WU Recombinant Human Erythropoietin Injection Major Product Offerings
7.13.4 SI HUAN SHENG WU Recombinant Human Erythropoietin Injection Sales and Revenue in Global (2017-2022)
7.13.5 SI HUAN SHENG WU Key News
7.14 Shanxi Weiqidaguangming Pharmaceutical
7.14.1 Shanxi Weiqidaguangming Pharmaceutical Corporate Summary
7.14.2 Shanxi Weiqidaguangming Pharmaceutical Business Overview
7.14.3 Shanxi Weiqidaguangming Pharmaceutical Recombinant Human Erythropoietin Injection Major Product Offerings
7.14.4 Shanxi Weiqidaguangming Pharmaceutical Recombinant Human Erythropoietin Injection Sales and Revenue in Global (2017-2022)
7.14.5 Shanxi Weiqidaguangming Pharmaceutical Key News
8 Global Recombinant Human Erythropoietin Injection Production Capacity, Analysis
8.1 Global Recombinant Human Erythropoietin Injection Production Capacity, 2017-2028
8.2 Recombinant Human Erythropoietin Injection Production Capacity of Key Manufacturers in Global Market
8.3 Global Recombinant Human Erythropoietin Injection Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Recombinant Human Erythropoietin Injection Supply Chain Analysis
10.1 Recombinant Human Erythropoietin Injection Industry Value Chain
10.2 Recombinant Human Erythropoietin Injection Upstream Market
10.3 Recombinant Human Erythropoietin Injection Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Recombinant Human Erythropoietin Injection Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer